Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
There is a compelling need for new treatment options that can offer high and durable clinical response," said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB.
- There is a compelling need for new treatment options that can offer high and durable clinical response," said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB.
- "Data presented at EADV showed that over 48 weeks many patients treated with bimekizumab achieved high thresholds of response.
- These findings suggest that inhibition of IL-17F in addition to IL-17A represents a promising treatment approach in moderate-to-severe hidradenitis suppurativa."
- "The bimekizumab Phase 3 clinical trial program in hidradenitis suppurativa included the more stringent clinical outcomes of HiSCR75, HiSCR90 and HiSCR100 in addition to the standard HiSCR50.